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1. Introduction 
In the past, heart valves were considered simple structures whose contribution to the 
unidirectional flow of blood was a merely passive movement in response to pressure gradients 
across the valve. It is now becoming apparent, however, that the heart valves have a more 
complex structure, consisting of vital and dynamic tissues composed of cells and extracellular 
matrix (ECM), specialized for the micro-environment in which they are placed, that respond and 
remodel in response to changes in local mechanical forces1,2. Cardiac valves are dynamic 
structures with a complex architecture highly specialized, consisting of a avascular, semi-fluid 
and deformable matrix enriched in Proteoglycans (PGs), Glycosaminoglycans (GAGs), collagen 
and elastic fibers. All these molecules give unique physical and mechanical features conferring 
to the valves the ability to bear high mechanical stresses during the normal cardiac cycle. GAGs 
into the ECM form a gel-like ground on which other molecules are deposited, forming 
permanent cross-links and interacting between them to make a network that limit the structural 
sollicitations due to bending and shearing stresses during the cardiac cycle. Heart valve disease 
has a devastating impact worldwide; every year numerous heart valve replacement procedures 
are performed (Fig. 1.1).  
Typical valve substitutes are mechanical prostheses and bioprostheses distinct in “Xenograft” 
and “Homograft”. During the last 15 years, tissue engineering (TE) approaches emerged in 
response to limitations associated with tissue and organ transplantation and with the scarcity of 
available donor tissue. It is believed that TE could assure the post implant recovery of normal 
function of the native valve. TE approaches to the construction of a heart valve, or any other 
tissue or organ, typically rely on three essential components: (1) cells, (2) scaffolds, designed to 
maintain the cells in a three-dimensional environment at the implantation site, and (3) signals 
that guide the gene expression and ECM production of the cells during tissue development2. 
Tissue engineering, defined as the regeneration of tissue by cell transplantation with the aid of 
supporting structures, is thought to overcome the obstacles of artificial tissue prostheses in 
cardiovascular surgery. Two major principles are followed in matrix research: (1) development 
of biodegradable polymer constructs emulating the initial anatomical structure; and (2) 
decellularization of preformed tissue, such as heart valves or blood vessels is under investigation. 
Decellularization generally refers to the removal of cells and cellular remnants while leaving a 
biological material composed essentially of extracellular matrix (ECM) components. The 
organization and remodeling of ECM is partially controlled by mechanical stresses and strains. 
GAGs and PGs are essential ECM components in valve tissues and have been shown to be 
segregated according to the type of loading that distinct regions experience101. The goal of the 
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current study was to provide insight onto decellularization approach to TEHV. The 
comprehension of which are the micro-structural effects on Glycosaminoglycans content caused 
by decellularization of the valve tissues and establishing functional limits are essential to the 
future development of a functional TEHV. 
 
 
Fig. 1.1 - (A) Mechanical prosthesis. (B) Bioprosthesis. (C) Tissue engineered. (Hoerstrup et al., Circulation 2002). 
 
1.1 Extracellular Matrix (ECM) 
Most cells in multicellular organisms are in contact with an intricate network of interacting 
extracellular collagens, PGs and adhesion proteins, as well as growth factors, chemokines and 
cytokines. Together, these components constitute the extracellular matrix (ECM). Many ECM 
proteins form large families and additional events, such as alternative splicing, proteolytic 
processing and post-translational events, increase the number of unique structures and expand 
the functions of these large, multifunctional molecules3.  The vascular ECM is a complex, 
dynamic, highly specialized and critical component of this tissue; it is characterized by a fibrillar 
component, containing mainly elastic and collagen fibers organized in supramolecular structures, 
and by an amorphous component forming a complex colloidal multiphase system distinct in an 
aqueous phase, in which are solubilized the electrolytes, and in a dispersed phase in which are 
present enzymes and the other molecules described above. These components interact and   
cross-link to form a biomechanically active polymer network that imparts tensile strength, elastic 
recoil, compressibility and viscoelasticity to vascular wall4-6. This network interacts with 
vascular cells and participates in the regulation of cell adhesion, migration and proliferation 
during vascular development and disease. Furthermore, components of the ECM bind plasma 
proteins, growth factors, cytokines and enzymes and these interactions modulate arterial wall 
metabolism. Thus, the vascular ECM not only maintains vascular wall structure but also 
regulates key events in vascular physiology4,7,8. The ECM scaffold-like provides tensile strength 
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and support suitable for tissue repairing, renewing and remodelling. The ECM as a fibers and 
soluble polymers network is evolved to stress absorber and maintain its shape; the composition 
of the ECM is controlled by the coordinate and differential regulation of synthesis and turnover 
of each of its components4. Such differential regulation creates differences in the composition of 
the vascular ECM during vascular development, between different vascular beds and in different 
forms of vascular disease9,10. For example, each layer of the vessel wall: Intima, Media and 
Adventitia has a different ECM composition. An ECM rich in fibrillar collagen, as is found in the 
adventitia, will impart stiffness and rigidity, whereas a layer enriched in PGs and hyaluronan, as 
found in the intima, is more viscoelastic and compressible. Maintaining the appropriate balance 
of the components in each layer is critical for maintaining vascular wall integrity and resisting 
rupture and hemorrage4. 
1.1.1 Glycosaminoglycans (GAGs) 
Complex polysaccharides are primary constituents of every eukaryotic cell surface and  
extracellular environment. GAGs are linear acidic polysaccharides containing a variable number 
of repeating disaccharide subunits, each consisting of an hexuronic acid linked to an hexosamine 
extensively N- and O-sulfated. There are four classes of GAGs based on their different chemical 
structures11: [1] chondroitin sulfate (CS) and dermatan sulfate (DS), [2] heparin (HE) and 
heparan sulfate (HS), [3] hyaluronan (HA), and [4] keratan sulfate (KS). The disaccharide units 
of the polymers are composed of an hexosamine often N-acetylated, Glucosamine (GlcN or 
GlcNac) or Galactosamine (GalN or GalNac), and an hexuronic acid, Glucuronic Acid (GlcA) or 
after epimerization at the C-5, Iduronic Acid (IdoA), linked by β(1,3) or β(1,4) glycosidic 
linkages12. GAGs adopt an extended conformation, attract cations, and bind water. Hydrated 
GAG gels enable joints and tissues to absorb large pressure changes. They are usually covalently 
linked at the reducing end to core proteins (PG) through an O-glycosidic linkage to a serine 
residue. The synthesis of GAGs takes place in the Golgi apparatus, and requires a host of 
nucleotide sugar transporters and glycosyltransferases13. A wide range of protein cores serve as 
acceptors for the initiation and polymerization of GAG chains. Serine is the anchor site in the 
protein for xylose, the first monosaccharide in GAG chains, to be attached through the action of 
a xylosyltransferase. The exceptions are keratan sulphate and hyaluronan. Keratan sulphate 
chains are linked to proteins either through GlcNAc–asparagines or GalNAc–serine/threonine 
linkages. Hyaluronan is synthesized as a GAG by HA synthases at the plasma membrane without 
covalent binding to a protein core14. The serine attachment site for GAGs polymerization is 
typically located in Ser-Gly dipeptide or repeating sequences with flanking acidic amino acids. 
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GAG synthesis is initiated by sequential addition of four monosaccharides forming the so called 
linker tetrasaccharide: GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-(Ser). The galactose units are 
transferred from UDP-galactose to the initiated chain by galactosyltransferase I and II, 
respectively. The last member of the linker unit is glucuronic acid (GlcA), transferred from 
UDP-GlcA by the enzyme glucuronosyltransferase I14-17. The growing GAG chains are modified 
at various positions characterizing and determining their biological roles (Fig. 1.2). These post-
translational modifications involve length chain, epimerization of GlcA to IdoA by C-5-uronosyl 
epimerase, and charge density due to O-sulphation in various positions both in the hexosamine 
units and the IdoA units, and occasionally in the GlcA units, through the actions of defined 
sulphotransferases. There are several specific sulphotransferases that have been identified, 
responsible for the transfer of sulphate units from the activated sulphate donor adenosine 3’- 
phosphate 5’- phosphosulphate (PAPS) to defined positions in the different types of GAG 
chains15-17. The chemical heterogeneity of GAGs in terms of their sulfation pattern and backbone 
chemical structure depends on the expression of these enzymes, and their tissue-specific 
isoforms and substrates. In ECM, PGs and GAGs, in addition to their structural role, participate 
in many physiologic and pathologic processes, such as cell migration, differentiation, cell 
adhesion and communication18-20, development of nervous system21, angiogenesis22,23 and 
embryogenesis24,25, atherosclerosis, cancer and microbial pathogenesis26-29. Chemical 
heterogeneity and other local variables in GAG chains allows specific ionic interactions with 
growth factors, cytokines, enzymes and other ECM molecules. 
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1.1.1.1 Hyaluronan (HA) 
Hyaluronan is an ubiquitous glycosaminoglycan synthesized as a large, negatively charged, 
unbranched polymer with diverse biological roles and a high molecular mass comprised solely of 
a repeating disaccharide of GlcA and GlcNAc linked by alternate β1-3 and β1-4 linkages that, 
unlike other GAGs, is neither sulfated nor attached to a core protein. This polysaccharide 
consists of 2,000–25,000 disaccharides, which corresponds to polysaccharides with relative 
molecular masses of 106–107 Da and polymer lengths of 2–25 μm31. The hyaluronan molecule in 
solution can be pictured as a highly organized extended dynamic coil that can undergo sharp 
kinks, bends and folds while still maintaining distinctive hydrogen-bond conformation32. It 
displays intriguing viscoelastic and conformational features, although it has a relatively simple 
regular structure. The lack of any chemical variation in the linear chain and its conformational 
flexibility make HA a versatile molecule that can form a variety of periodic multi-molecular 
structures through its interaction with specific HA-binding proteins, known as hyaladherins. It is 
thought that these capture, stabilize, and propagate particular conformations of the 
polysaccharide leading to HA–protein complexes with different architectures and specific 
functional activities30. Hyaluronan has remarkable hydrodynamic characteristics, especially in 
terms of its viscosity and its ability to retain water. It therefore has an important role in tissue 
homeostasis and biomechanical integrity, and these properties form the basis of its widespread 
use in tissue engineering. Hyaluronan also forms a multivalent template for interactions with 
proteoglycans and other extracellular macromolecules that is important in the assembly of 
extracellular and pericellular matrices31. It is found in cartilage and synovial fluid where plays a 
critical dynamic role in both energy dissipation of fast compressive shock of the joint surface and 
control of fluid flow through the joint synovium32, connective tissue and vitreous humour31. 
1.1.1.2 Chondroitin Sulfate Isomers (C4S, C6S, DS) 
These GAGs are the most abundant in the human body, above all in the cartilagineous tissues, in 
the intervertebral disks, in the skin, tendons, in the cornea and aorta33. They are the only ones to 
contain the amino sugar galactosamine: the 4-sulphate (chondroitin A) and the 6-sulphate 
(chondroitin C) are homopolymers of disaccharides consisting of GlcA and GalNac, which is 
esterified mainly in position 4 or 6 with sulphate groups. The number of repeated disaccharides 
varies according to the tissue with an average of 40 for chain. The DS (chondroitin B) shows a  
copolymeric nature containing both GlcA and IdoA. The two residues within each disaccharidic 
unit are linked by β(1,3) linkages, while the various units are united by β(1,4) linkages. Their 
ratio varies according on tissue type and also within the same tissue. The sulphation can be in 
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position 4 or 6 in GalNac or in position 2 in IdoA or GlcA. The number of disaccharides 
repeated for chain is about 50-60. 
1.1.1.3 Heparin (HE) and Heparan Sulfate (HS) 
These GAGs, like DS, are linear copolymers containing both GlcA and IdoA linked by α(1,4) 
glycosidic linkage to GlcNac, while the various disaccharide units are linked by β(1,4) linkages. 
The two GAGs are distinguished by the size of the chains, the IdoA percentage and the number 
of sulfoester groups present in both hexuronic acid and hexosamine. IdoA prevails in HE, mainly 
O-sulfate in position 2; also the hexosamine is sulfated in position 4 or 6, and a fraction of the N-
acetyl groups is replaced with N-sulfates. HE is distinguishable from HS by its high levels of 
such modifications. In heparin, approximately 80% of the disaccharide units are modified, while 
less than 10% of HS disaccharide units are epimerized or sulfated; HE is synthetized in mast-
cells and plays a key role in the  coagulation, while HS is synthetized by fibroblasts and 
endothelial cells and has been implicated in a wide variety of biological processes such as 
growth factor signaling, cell adhesion, wound healing, and tumor metastasis. HS is found on the 
surface of many cell types, in ECM of connective tissue, and in the basal membranes34. 
1.1.1.4 Keratan Sulfate (KS) 
Disaccharidic unit of KS is characterized by a residue of D-galactose instead of hexuronic acid 
linked by β(1,4) linkage to GlcNac, while the disaccharidic units are linked by β(1,3) linkages. 
Both the residues of each units may contain a sulfate group in position 6. There are two classes 
of KS: type I (KSI), isolated from cornea where affects its transparency, is bound to protein core 
through a N-glycosidic link between GlcNac and a asparagine residue; Type II (KSII), isolated 
from cartilage, is bound to protein core by a O-glycosidic link between GlcNac and a Serine or 
Threonine residue16. 
1.1.2 Proteoglycans (PGs) 
Proteoglycans (PGs) are proteins with long, unbranched polysaccharides chains (GAGs), 
ubiquitously expressed, and displaying a wide range of functions. After synthesis PGs are 
transported from the Golgi to their destinations: the extracellular matrix (ECM), the cell surface 
or intracellular organelles. Such vectorial transport requires mechanisms for recognition, sorting 
and delivery, which are especially important in cells, such as epithelial cells and neurons, where 
the cell membrane comprises separate domains. Recognition and sorting must require 
determinants in the GAG chains and/or in the PG protein cores16. Initially, PGs were grouped 
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together because of the high negative charges of their GAG chains which make separation from 
other molecules by ion-exchange chromatography easy, and classified on the basis of the 
predominant type of GAG attached to the core proteins. However, PGs are not similar. The core 
protein size ranges from 10 kDa to > 500 kDa, and the number of GAG chains attached varies 
from one to >100. In addition, several PGs carry GAG chains of more than one type (hybrid 
PGs) and/or have additional N-linked or O-linked sugar modifications16. Furthermore, more 
recent comparisons of PG core protein structure by immunochemical and cloning methods have 
shown that these molecules exist as multigenic families, making a scaffold for GAG chains, and 
containing domains with particular biological activity4. PGs are placed in four main areas:         
1) throughout the ECM, 2) associated with specialized structures of the ECM, such as basement 
membrane and basal laminae, 3) cell surface and 4) in intracellular structures, such as secretory 
storage granules and synaptic vesicles, suggesting that these molecules have numerous biological 
functions. GAG chains are large extended structures, with various alcoholic and acidic groups, 
and they dominate the physical properties of the protein to which they are attached. PGs in the 
ECM thus function physically as creators of a waterfilled compartment. Their high fixed 
negative charge attracts counter ions, and the osmotic imbalance caused by a local high 
concentration of ions draws water from the surrounding areas. Thus, PGs keep the matrix 
hydrated. A further physical property of the GAG chain is that they exclude other 
macromolecules while retaining permeability to low molecular weight solutes. The PGs thus 
create a water compartment, only part of which is available to other matrix macromolecules. 
This increases the concentration of the macromolecules and therefore may increase reaction rates 
promoting all interactions that are concentration dependent35-37. Although PGs constitute a minor 
component of vascular tissue, these molecules have been shown to influence a number of arterial 
properties such as visco-elasticity, permeability, lipid metabolism, hemostasis, and thrombosis33. 
The distribution of PGs throughout the blood vessel wall is variable and minimal variations in 
the GAG structure are responsible of the consistency of the existing several ECM (rigid, elastic 
and anelastic) determining its function. Versican/HA, Biglycan, Decorin, Perlecan, and 
Syndecan are the main PGs expressed in connective vascular tissue; content and distribution of 
these molecules is related to elderly and particular physiopathologic conditions47. 
VERSICAN belongs to the family of hyaluronan-binding proteoglycans that include aggrecan, 
neurocan and brevican, constituting a gene family collectively termed ‘hyalectins’. These PGs 
are components of the ECM and are found in a large number of tissues. Versican is a CS 
proteoglycan with a protein core of 263 kDa and binds 15-20 GAG chains, approximately. The 
gene and protein structure of versican follows a domain template. Successful cloning has 
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revealed the existence of at least four splice variants of versican, which differ in the size of the 
core protein and the number of glycosaminoglycan chains. The amino-terminal globular end 
(G1) binds to the hyaluronan, and the carboxy-terminal globular domain (G3) resembles the 
selectin family of proteins, consisting of a C-type lectin domain adjacent to two epidermal 
growth factor (EGF) domains and a complement regulatory region. The middle region of the 
versican core protein is encoded by two large exons that specify the CS attachment regions of 
versican38. Versican is present throughout the interstitial space of the vascular ECM and interacts 
with hyaluronan and link proteins to fill the ECM space not occupied by the fibrous components. 
These complexes create a reversibly compressible compartment and provide a swelling pressure 
within the ECM that is offset by the collagen fibrils4. 
BIGLYCAN and DECORIN are small PGs that belong to the family of small leucine-rich 
proteins (SLRPs). These PGs contain an N-terminal domain that is usually substituted with either 
one (decorin) or two (biglycan) chondroitin/dermatan sulfate side chains, leading to pronounced 
polyanionic properties. The most salient feature of decorin and biglycan is the presence of 10 
leucine-rich repeats (LRRs) flanked by cysteine-rich regions. Both biglycan and decorin are 
known to bind to different types of collagens39,40, their major functional roles include regulation 
of collagen fibrillogenesis, modulation of growth factor activity, and regulation of cellular 
growth. Decorin protein core (37 kDa) form a superhelix and is arranged so that the b-strands 
and a-helices are parallel to a common axis, thereby forming a horseshoe structure with the       
b-sheets lining the concave surface of the molecule and the a helices flanking the convex face. 
The concave surface can accommodate one triple helix of collagen type I and could account for 
the proposed binding sites and functional role of decorin in regulating collagen 
fibrillogenesis41,42. Biglycan protein core (38 kDa) was identified as a molecule that accumulates 
at the cell surface and in pericellular environments. Thus, based on its discrete cellular location, 
biglycan may have a different biological function in morphogenesis and differentiation36,43, and 
interact with several apoproteins44. 
PERLECAN and SYNDECAN are PGs associated to basement and plasma membrane, 
respectively. Perlecan (470 kDa protein core) is a modular HSPG and is one of the largest single-
chain polypeptides found in vertebrate and invertebrate animals. The various modules of 
perlecan and its HS chains take part in a large number of molecular interactions. Its binding 
partners include numerous heparin-binding growth factors such as fibroblast growth factor-2 
(FGF2), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), 
and other proteins that are constituents of basement membrane or cell surfaces. Perlecan is also 
expressed in avascular tissues such as cartilage and various connective tissue stromas. So, it is 
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not surprising that perlecan is involved in a number of pathological processes, including 
atherosclerosis, angiogenesis and cancer45,46. The syndecans (31 kDa protein core) are a family 
of polymorphic cell surface proteoglycans bearing heparan sulfate and chondroitin sulfate 
chains. Their structure incorporates a short COOH terminal cytoplasmic domain, a 
transmembrane domain, and a large extracellular domain with numerous binding sites for GAG 
chains36. The cytoplasmic domain contains tyrosine residues that may provide phosphorylation 
sites for protein kinases, which are key enzymes in many signal transduction pathways, or may 
form sites for cross linkage with cytoskeletal elements. Syndecan interacts with growth factors, 
ECM receptors, coagulation enzymes, lipases, cytokines, fibronectin and collagen type I and II4. 
1.1.3 Collagens 
Collagens are proteins that consist of a triple helix of polypeptide chains, in which each chain 
contains at least one stretch of the repeating amino acid sequence Gly-X-Y. Six collagen types 
have been identified in blood vessels (I, III, IV, V, VI and VIII), of which type I and III comprise 
up to 80-90% of the total blood vessel wall48,49. Type I and III collagens are organized into 
distinct fibrillar bundles, either wedged between elastic fibers in elastic arteries or organized into 
nests surrounding medial arterial smooth muscle cells in muscular arteries50,51. These collagens 
provide tensile strength to the vascular wall. Type IV and VIII collagens are present within 
vascular basement membranes beneath endothelial cells and surrounding arterial smooth muscle 
cells. These molecules self-associate and interact with other molecules to form a supramolecular 
networks that serve as an anchoring substrates for vascular cells and as a permeability barrier to 
plasma proteins52. Type V and VI are present in small amounts in vascular tissue; the first 
codistributes with type I and may participate in the formation of collagen heteropolymers. A 
recent survey in human vascular tissue indicates its presence in thickened arterial intimas and in 
atherosclerotic fibrous plaques53. The second appears in all vascular layers between types I and 
III48,49; recent studies suggest that the type VI collagen fibril is bound with other ECM 
molecules, such as PGs, and may serve as an adhesive substrate for vascular cells54,55. The 
principal source of collagens biosynthesis is the smooth muscle cell; defects in the synthesis and 
deposition are associated to fibrous degenerative pathways such as atherosclerosis. 
1.1.4 Elastic fibers 
Another major component of blood vessels is the fibrous protein elastin, that provides 
mechanical strength and elasticity needed to accommodate pressure changes and hemodynamic 
changes due to pulsatile nature of blood flow. Elastic fibers are arranged into concentric sheets 
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or lamellae that separate different vascular layers. Frequently, the elastic lamellae are 
interconnected by radially oriented elastic fibers that facilitate the transfer of stress throughout 
the vessel wall50,51. The principal source of elastic fibers biosynthesis is the arterial smooth 
muscle cell that synthesize it as a precursor molecule: tropoelastin. 
1.2 Cardiac valves 
1.2.1 Morphology  
Cardiac valves are specialized forms of cardiovascular connective tissue designed to bear high 
mechanical stresses during the normal cardiac cycle. The valves show a complex architecture 
highly specialized, consisting of a avascular, semi-fluid and deformable matrix enriched in PGs, 
GAGs, collagen and elastic fibers. The four heart valves arise from embryonic mesenchymal 
outgrowths referred to as the endocardial cushions in a process termed valvuloseptal 
morphogenesis; two valves form in the atrioventicular canal (the tricuspid and mitral valves), 
with two valves forming in the ventricular outflow tract (aortic and pulmonary semilunar 
valves). It has been long accepted that all heart valves were simple structures whose contribution 
to the unidirectional flow of blood was merely passive movement in response to pressure 
gradients across the valve56. It is now clear that valves show several key characteristics as 
viability, sufficient strength to withstand repetitive and substantial mechanical stress, and ability 
to adapt and repair injury by connective tissue remodeling1. The four cardiac valves have 
microstructural similarities; however, the aortic valve best illustrates the essential features and 
serves as a paradigm for microstructural and cellular adaptation to functional requirements; 
furthermore, it is the most frequently diseased and also commonly transplanted. The semilunar 
valves are membranous sac-like flaps that show a sticking edge implanted on the fibrous ring 
placed on the border of the artery ostium and a free edge that protrude in the vasal lumen. The 
aortic valve cusps undergo substantial changes in shape and dimension during the cardiac cycle. 
Microscopically, the aortic valve is composed of three distinct layers: (1) the ventricularis 
closest to the inflow surface, rich in elastin, (2) the fibrosa closest to the outflow surface, 
primarily composed of densely packed collagen, and (3) the centrally located spongiosa, largely 
composed of GAGs1-2. Together, collagen, elastin, and GAGs comprise the valvular ECM. 
Studies of normal, pathological, and substitute valves have demonstrated that the principal 
determinant of valve durability is the valvular ECM, whose quantity and quality depend on the 
viability and function of valvular interstitial cells (VICs)57. The principal cell types in the heart 
valve are the valvular interstitial cells (VICs) and valvular endocardial cells (VECs), smooth 
muscle, cardiac muscle and nerve cells2. VICs, believed to be responsible for maintenance of 
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valvular structure, are numerous, elongated cells with many long, slender processes extending 
throughout the valve matrix. They connect to each other to establish a three-dimensional network 
throughout the entire valve, and are intimately associated with the valve matrix. It has been 
suggested that there may be two morphologically and structurally distinct populations of VICs: 
one possessing contractile properties, characterized by prominent stress fibers, and one 
possessing secretory properties, characterized by prominent rough endoplasmic reticulum (rER) 
and Golgi apparatus2. VICs are also the essential components of the intrinsic repair system of the 
valve. This regenerative process appears to be vital to normal valvular function and the absence 
of VICs in current prosthetic heart valve models is a probable factor contributing to structural 
failure2. The other major valve cell type is the VEC, which forms a functional envelope around 
each of the four heart valves. It seems reasonable that the VECs act to maintain a 
nonthrombogenic valve surface, similar to the vascular endothelium. Ultrastructurally, VECs 
have been shown to possess cell junctions, plasmalemmal vesicles and rER1,2. Forces acting on 
the valve at the macroscopic level such as pressure, shear stress, and tension, that during the 
cardiac cycle regulate the leaflet opening and closing and cause complex deformation of these 
structure, are translated into specific biomechanical responses at the tissue level, consisting in 
collagen uncrimping, reorientation, and fiber compaction, which are in turn transduced into a 
VIC response at the cellular level with intracellular signaling events leading to changes such as 
increased alpha smooth muscle actin (α-SMA) expression, increased VIC stiffness, and increased 
ECM biosynthesis1,2. The pressure stresses are higher in the commissure and greater during the 
diastole regarding the systole. The entity of stresses in this area suggests that absence of 
continuous and rapid tissue turnover may lead to tissue usury and fatigue followed by its 
rupture58. Complex microstructural rearrangements and several specializations of collagen 
accommodate the cyclical pressure fluctuations during the cardiac cycle. Collagen fibers in a 
planar orientation in the fibrosa comprise the strongest portion of the leaflet that is responsible 
for bearing diastolic stress. GAGs in the spongiosa probably serve predominantly as a shock and 
shear absorber. The large cuspal deformation during the cycle between systole and diastole is 
facilitated by biomechanical cooperativity between collagen and elastin. Collagen fibrils are 
inelastic and incapable of supporting large strains; therefore, they have adaptations, macroscopic 
corrugations and microscopic crimp, that permit collagen stretching at minimal stress by 
unfolding. During valve opening, elastin stretches during extension of collagen crimp and 
corrugations. When the valve is closed, the collagen is fully unfolded and the load is shifted from 
elastin to collagen; elastin restores the contracted configuration of the cusp during systole1. 
GAGs are the major structural components of ground matrix found in connective valvular tissue. 
Introduction 
 
Antonio Cigliano, “Aortic and pulmonary bioprosthetic heart valves: an insight on glycosaminoglycan distribution and fine structure in 
decellularized porcine scaffolds for tissue engineering purposes” Dottorato in Biochimica, Biologia e Biotecnologie Molecolari – Università degli 
studi di Sassari. 12 
 
The nature and relative proportions of GAGs found in normal human valvular tissue and the 
changes occurring in these components as result of both their location, (aortic, mitral and 
tricuspidal valve) and aging have been described59. Occurrence of increased fibrosis, 
accompanied by calcification, degeneration of collagen fibers, and decrease in GAG content with 
age has also been demonstrated60. These changes were more prominent in aortic valve than in the 
others, with a GAG decrease of about 50% in the aortic valve, 25% in the mitral and 15% in the 
tricuspidal  in men over 60 years old59. In normal human valves the major GAG components are 
HA (~ 60%), CS (~ 25/30%), and DS (~ 10/15%). Although GAG content is influenced by age, 
relative proportions of these three types of GAGs are not subjected to changes with aging59. 
Differently from the human, the porcine and bovine cardiac valves are mainly constituted of CS 
and DS61. Similarly to the human, the bovine aortic valves are richer in GAG content regarding 
those pulmonary and subject to a major decrease of the biosynthetic sulfate GAG activity with 
age62. The different GAG composition between these valves is probably associated to various 
pressure gradients or stresses to which they are subjected. 
1.2.2 Heart valve substitutes 
Valve replacement represents the most common surgical therapy for end-stage valvular heart 
disease63, and approximately 275,000 procedures are performed globally each year (Rabkin and 
Schoen, 2002). Exploration into heart valve replacement began in the 1950s, with the first 
successful human valve implantation being performed in 1952. Subsequent decades saw the 
development of numerous models of prosthetic heart valves with a progressive improving of 
design and manufacture technology; these remain the most common treatment for advanced 
heart valve disease64. 
Originally, the optimal characteristics of the artificial heart valves were listed by Harken65: 
? Not obstructive; 
? Immediate and complete closure; 
? Not thrombogenic; 
? Infections resistant; 
? Chemically inert and not hemolytic; 
? Life span (years); 
? Easy to insert in the appropriate physiological site. 
In the reconstructive heart surgery, the bio-grafts may be either mechanical, consisting entirely 
of synthetic components, or obtained by biological tissue, bioprosthesis, distinguished in 
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allograft/homograft (human source) sterilized and cryopreserved, and xenograft (animal source) 
glutaraldehyde-fixed to reduce its immunogenicity and to stabilize it against the proteolytic 
degradation that would otherwise occur once implanted into the patient. Tissue crosslinks are 
formed by means of a number of complex reactions through which covalent bonds are created 
between the primary amine groups of proteins and the reactive aldehyde functionalities of 
glutaraldehyde (Glut). The result is a tightly crosslinked matrix of proteins, the majority of 
which is collagen. The leaflets maintain their flexibility, but there are structural modifications 
due to fixed non viable cells, and therefore incapable of a normal turnover and remodelling of 
the ECM components. The microstructure of the cusps, blocked in a phase of the cardiac cycle, 
show an alteration of the mechanical properties respect to the native cusps; at microscopic level, 
cuspal ECM components lacking free amine functionalities, such as elastin and GAGs, are not 
effectively stabilized, causing a loss of the endothelium, changes in spatial orientation of 
collagen and elastin fibers, decrease in GAG content and sovramolecular PG complex, rupture of 
plasma membrane and alteration of fibroblasts66,67. The major advantage of mechanical heart 
valves is their durability and longevity. However, the body’s natural response to foreign 
materials can often result in thrombosis68, which can lead to mortality. For this reason, patients 
receiving mechanical heart valves are placed on long-term anticoagulation therapy69. Other 
limitations with mechanical valves are their association with infective endocarditis, risk of 
failure or separation of valvular components which may become embolised70. On the other hand, 
advantages of xenografts include an unlimited supply of donor tissue and superior 
hemodynamics with respect to mechanical valves; however, progressive tissue deterioration and 
calcification afflict biological replacements. Therefore, efforts of researchers are directed 
towards a better knowledge of heart valve structure and ECM component interactions that can 
significantly affect its life span. The main drawbacks of bioprosthetic heart valves (BHVs) are 
the following: 
 Post implant cells are not viable; 
 Collagen scaffold is chemically and mechanically altered; 
 ECM does not repopulated; 
 Cell debris facilitate calcification process. 
In particular, numerous studies suggest that the maintenance of structural and functional ECM 
integrity is of primary importance for the performance of the valve substitutes. Depletions or 
alterations of the ECM components could be responsible for graft deterioration64. Over time, 
these bioprostheses become less extensible and progressively calcified, eventually leading to 
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structural deterioration, leaflet tears, and valve failure. Calcification and structural tear are 
synergistic processes affecting mainly the ECM during graft preparation. The principal changes 
described are: loss of endothelium and consequently loss of cohesion collagen fibers, mechanical 
damages due to fixation, absence of viable cells with consequent impossibility to renewing and  
remodeling the ECM. Moreover, because GAGs play an important role in maintaining tissue 
viscoelasticity, their loss from bioprosthetic valves might compromise mechanical function 
determining failure of valve integrity66,67,71-73. Several studies have been gathered on the 
improvement of fixation techniques; in fact, bioprostheses show an intrinsic calcification as 
consequence of the inability of the non viable cells to maintain a normal flow of intracellular 
Ca2+. Calcific degeneration is often due to mechanical dysfunctions and vascular obstruction1,58. 
Moreover, the GLUT-fixation seems to enhance mineralization, indicating that calcific 
mechanism could depend from specific biochemical modifications induced by aldehydes at 
microstructural level66,74. The first Ca2+ storages are localized to the insertion areas of the cusps, 
the regions that are much more subjected to mechanical stresses58. The other cause of the valve 
grafts failure, in synergy with the calcification process, is the non-calcific structural degeneration 
due to the absence of physiological mechanisms of ECM self repairing. The factors involved in 
the ECM injuries are the anomalous movement of the valves, the inhibition of the structural 
rearrangement during the normal valve functioning, and the loss of the cell-mediated 
remodelling ability66. Molecular and biochemical alterations of collagen and elastin fibers and 
ECM degradation caused by the action of matrix metalloproteases (MMPs), collagenases, and 
high levels of β-glucuronidases could contribute to the progressive structural deterioration and 
calcification, suggesting that the tissue failure is related both to mechanical/calcific damages and 
to the action of proteolytic enzyme either intrinsic (immobilized tissue proteases derived by non 
viable cells) or extrinsic (infiltration of plasma components)66. On the other hand, GAGs because 
of the high concentration of negative charges and their inherent hydrophilicity are capable of 
absorbing a large amount of water within the tissue matrix. As a result, they are important 
components of the extracellular matrix of native heart valve cusps, especially with regards to 
mechanical behavior. It has been speculated that their ability to hydrate the spongiosa layer 
serves to decrease the shear stresses associated with cuspal flexure during valve function. In 
addition, the ability of this hydrated layer to absorb compressive forces may reduce buckling 
during flexion, which has been attributed to the mechanical failure of BHV cusps. Furthermore, 
the presence of negatively charged GAG molecules within the extracellular matrix of cuspal 
tissue may reduce calcification by chelating calcium ions, thereby preventing hydroxyapatite 
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nucleation. These observations suggest that the loss of GAGs may be an important factor in the 
structural and/or calcific failure of bioprosthetic heart valves67,75. 
Regarding to homograft and allograft, sterilization and cryopreservation techniques are designed 
to obtain hydraulically functional valves with minimal cellular and tissue injuries. 
Cryopreservation induces damages to cellular level; in fact, it has been described an alteration of 
cytosolic and mitochondrial functionalities in endothelial cells76 and fibroblasts77. The 
maintening of cellular viability could be crucial in the restoration of those components of the 
ECM depleted or altered during tissue processing (ischemic interval, storage temperature, and 
the preservation modality)78. In particular, fibroblast viability is essential, because it play a key 
role in the turnover of the ECM components, in that sites subjected to elevated mechanical 
stresses58,79. To this aim, it is to emphasize that cellular viability in cryopreserved substitutes 
prepared by the standard protocols of Homograft Italian Bank, has been estimated between 80-
90%77, although there is progressive loss of metabolic functioning in valve leaflet cells as storage 
times increase80. Homografts and allografts display a high hemodinamic profile, low incidence 
of thrombo-embolic complications, and infection resistance81. Current preservation techniques 
aim for a high degree of cellular viability at the time the graft is implanted. A previous research 
indicates that donor cells seem to disappear rapidly and will, in part, be replaced by host cells80. 
Furthermore, it is known that cryopreserved valves are capable of evoking cellular and humoral 
immune responses in vitro and in vivo. It is uncertain, however, whether the immunogenicity of 
these valves contributes to the loss of valve cellularity and structure and thereby to their 
dysfunction and failure80. The failure of this type of grafts is to ascribe to the insufficient ability 
to cell growing, repairing, and remodelling, causing the progressive tissue deterioration 
associated to calcium phosphate storages in correspondence of the regions subjected to high 
mechanical stresses (commissures) including ECM injury, collagen type I damages, and loss 
and/or modifications of GAGs82-85. However, although the choice of homograft/allograft is better 
than xenograft or mechanical prostheses their insufficient availability has always limited the 
use64. 
Several studies are focusing on the potential applications of tissue engineering (TE) in 
regenerative medicine that range from structural tissue to complex organs. Essentially, TE 
consist in the development of a scaffold, a biocompatible and biodegradable decellularized 
structure, seeded with cells to obtain a new, functional tissue. The scaffold should temporarily 
supply as biomechanical support until the seeded cells produce a new ECM, and it depends by 
the ability to the seeded cells to renew, to repair and to remodel themselves recreating a structure 
similar to the native64. A widely accepted paradigm of tissue engineering comprises [1] a 
Introduction 
 
Antonio Cigliano, “Aortic and pulmonary bioprosthetic heart valves: an insight on glycosaminoglycan distribution and fine structure in 
decellularized porcine scaffolds for tissue engineering purposes” Dottorato in Biochimica, Biologia e Biotecnologie Molecolari – Università degli 
studi di Sassari. 16 
 
scaffold, that is pre-seeded with [2] cells, followed by [3] an in-vitro stage of tissue formation 
typically conducted in a bioreactor, that recapitulates a physiological metabolic and mechanical 
environment, and subsequently, following implantation of the construct, [4] an in-vivo stage of 
tissue growth and remodeling. The key pathophysiological processes occurring during the in-
vitro and in-vivo phases are cell proliferation and migration, ECM production and organization, 
scaffold degradation, and tissue remodeling. The in-vivo but not the in-vitro phase can involve 
recruitment of the recipient’s inflammatory cells. The resulting tissue engineered construct will 
likely contain some combination of seeded and/or recipient-derived new cells. 
An alternative pathway utilizes an unseeded scaffold that incorporates biological “information” 
designed to attract and direct the formation of circulating endogenous precursor cells, potentially 
both endothelial and mesenchymal, in-vivo. Moreover, host inflammatory cells may play a role 
in the in-vivo phase of either approach1. 
Scaffolds can be obtained from biodegradable synthetic polymer and/or natural allograft or 
xenograft decellularized tissues. Both types show advantages and disadvantages: synthetic 
scaffolds allow to control material structure and properties like pore size, stability, degradation 
rate, and they are easily reproduced; however, they are resorbable and present difficulty in 
controlling cell adhesion and tissue reorganization, inflammation due to incomplete polymer 
degradation or lack of biocompatibility, space formerly occupied by polymer and its interstices is 
replaced by fibrosis that limits perfusion to deep cells. Natural scaffolds maintain architecture of 
the native tissue and biological information (reactive sites, growth factors), but they are 
potentially resorbable, decellularization may alter physical properties, difficulty of cell 
penetration into interior, may induce immunologic reaction and potential for calcification1. 
Potential cellular sources for seeding of scaffolds to fabricate heart valves include differentiated 
tissue-specific cells such as allogenic or xenogenic endothelial cells and/or fibroblasts86,87, 
autogenic smooth muscle cells, interstitial cells and fibroblasts88, and stem cells that may be 
autologous or allogenic avoiding the problem of cell phenotype preselection88. Following 
extensive studies using ovine vascular derived cells and regarding future human application the 
suitability of human cells derived from various human cell sources have been investigated. 
Among the most promising are vascular-derived cells, bone marrow-derived cells, blood-derived 
cells, umbilical cord-derived cells and chorionic villi-derived cells, particularly for pediatric 
application89. Seeded cells can then use the body’s natural structural cues to promote 
organization, growth and development of the replacement ‘tissue’. The scaffolds are designed to 
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However, successful tissue regeneration may not always be achieved ‘simply’ by combining 
cells and scaffolds. The gene expression of cells and tissue formation can be regulated or 
promoted by the addition of growth factors, cytokines or hormones2,86,90. The mechanisms of 
valve morphogenesis, during the embryonic development, are complex and highly regulated, 
therefore it could be difficult to stimulate all the mechanisms involved in the regulatory 
pathway64. With this approach it is possible to obtain a viable and autologous TE that can be 
implanted promoting the development of cardiac valves mimicking growth, repair and remodel 
such as native tissue. Inherent studies are needed regarding the progressive evolution of this 
structures, the gene expression and the functionality of the viable cells, the composition and 
organization of the new ECM, the effect due to the mechanical deformation of the ECM on the 
cellular increase, cell-cell and cell-matrix interactions. 
Although, TE constitute the ideal substitute as it arranges nearly all the characteristics of a native 
valve, we are still far to obtain adequate outcomes for the implant in the man. Meantime, parallel 
studies are trying to improve the quality of bioprostheses and mechanical prostheses performing 
their hemodynamic characteristics and limiting the calcific/non calcific injuries due to 
deterioration of the substitutes, with the intent to increase the graft durability and to reduce the 
necessity of repetitive surgeries. 
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2. Aim of this work 
GAGs are heterogenous polysaccharides not only for the type of constituent disaccharidic unit 
but above all for their molecular size, charge density, sulfation pattern, and epimerization 
degree12,15. With the exception of hyaluronan, GAGs are usually linked to a protein core forming 
PGs. PGs are implied in numerous biological processes and the majority of these functions is 
mediated by the structural characteristics of their GAG chains. The structural analysis of GAGs 
implies the characterization of disaccharide components, whose features determine the 
bioactivity of the molecules. The structural analysis of GAGs consist in chemical or enzymatic 
depolymerization, followed by separation and characterization of the products by electrophoretic 
(Capillary Zonal Electrophoreses CZE, Fluorophore Assisted Carbohydrate Electrophoresis 
FACE)91-93 or chromatographic (HPLC) techniques94. PGs are essential components of the ECM, 
playing structural and functional key roles in the valve tissue; in fact, they are differently 
distributed in the cardiac valves and their turnover is higher at commissure level, where 
mechanical stresses are maximal4. Qualitative and quantitative modifications of these molecules 
due to GAG structural modifications and/or altered rates of turnover can be associated to several 
pathological diseases. Since GAGs/PGs influence the abilities of cell population to grow onto 
acellular scaffold (bioprosthesis) or cryopreserved grafts (homograft), the study of their content 
and composition in cardiac valves could reveal key factors in tissue engineering and 
development of valve bioprostheses. 
In a recent publication, cryopreservation has been reported to determine a marked loss of cellular 
viability and tissue integrity. Moreover, a relevant GAG content depletion, with possible 
consequences on the graft performance64, and the presence of low-sulfate chondroitin sulfate83,84 
have been observed. A loss of GAGs has been also described in the fixed tissue during the 
preparation of bioprostheses, probably affecting the potentiality of repopulation of these devices. 
While a limited number of reports have described the intact valve GAGs, little attention has been 
made to the complex valve microstructure and GAG fine structure, i.e. the relative abundance of 
variously sulfated disaccharides. Sulfation patterns of GAG chains are thought to be critical for 
GAG function and cellular signaling109. Reports characterizing valve GAGs are even fewer and 
largely regard bioprosthetic valves and tissue engineering heart valves (TEHVs). 
The aim of this study was to characterize the composition as well as the fine structure of GAGs 
in native and decellularized porcine aortic and pulmonary valves to assess eventual GAG 
compositional changes during development of a scaffold for TEHVs. Therefore, we have 
compared GAG content, composition, and structure in control fresh valves (NT) and in valves 
subjected to a decellularization treatment (TRICOL) depicted to completely eliminate the 
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cellular components maximizing the maintenance of the endothelial basal membrane, the ECM 
structural network and its integrity, the interactions of small PGs with collagen fibrils, and the 
mechanical properties of the valve95,96,110. The fine structural analysis of GAGs from different 
valve regions was performed by means of fluorophore-assisted carbohydrate electrophoresis 
(FACE). 
Finally, the objective is to obtain a scaffold suitable to the cellular repopulation and to get useful 
informations for the improvement of the graft preparation procedures. Detailed structural GAG 
analysis is appeared irrenounceable for the reason that selective depletions and/or modifications 
of GAGs following decellularization processing could influence preparation of the biological 
valve substitutes, their ability to recellularization, ECM remodelling and renewal, their resistance 
to calcification, structural deterioration, and non-thrombogenic nature. 
This work was conducted in collaboration with the researchers of Biomedical Experimental 
Sciences Department, University of Padua. 
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3. Materials and methods 
3.1 Tissue analysis 
Porcine hearts from 10-12 month old pigs with weights ranging from 160 to 180 kg were 
obtained from a local slaughterhouse. Within 2 hours from death valve conduits were harvested 
and decellularizated by a detergent-based procedure. We have analyzed 24 semilunar porcine 
valves divided in 2 groups: 12 aortic and 12 pulmonary valves; for each group 6 samples were 
considered as control and referred to as NT and 6 samples decellularized and referred to as 
TRICOL. All tissue sampling and decellularization steps were conducted by our colleagues in 
Padua. Briefly, NT samples were rinsed in isotonic saline solution and immediately processed. 
TRICOL samples were extracted for 10 h with 1% (w/v) Triton X-100 in presence of protease 
inhibitors (PI). After further 10 h extraction without PI and washing overnight in 0.1% (w/v) 
Triton X-100, samples were extracted at 4°C for two 10-h periods in PBS containing 0.5M NaCl. 
Following hypotonic PBS washing, Triton X-100 was replaced by 10 mM sodium cholate, and 
extraction resumed for two 10-h periods at room temperature. All samples were finally washed 
in 10% (v/v) isopropanol, saline, equilibrated in water and wet weight recorded. All extraction 
procedures were carried out in presence of NaN3 0.1‰ in fully degassed solution containing 10 
mM sodium ascorbate and under N2 atmosphere. Tissue processing for the GAG analysis is 
delivered in the flow diagram in Fig. 1. 
Three zones were cut using a surgical blade and separately processed: the aortic root wall, the 
commissure, and the leaflet. After peeling and segregation of the three different types of tissue, 
their wet weight was measured. Tissues were fixed with 20 volumes of acetone at 4°C for 24 h, 
delipidated with 20 volumes of chloroform:methanol (2:1, vol/vol) at 4°C for 24 h, and, after 
centrifugation at 3300 x g for 15 minutes, dried at 60°C. The final weight (dry defatted tissue 
[DDT] weight) of the artery wall, commissure, and the leaflet was recorded. 
3.2 Extraction and purification of total GAGs  
DDTs (100 mg) were rehydrated for 24 h at 4°C in 0.1 M sodium acetate, pH 6.0, containing 5 
mM cysteine and 5 mM ethylenediaminetetraacetic acid (37 volumes for gram of DDT). Papain 
(0.3 U/mg of DDT) was then added to the mixture, which was incubated at 56°C for 24 h under 
mild agitation. The digest was clarified by centrifugation (9000 × g for 20 min at +4°C). Digest 
supernatant was loaded on a (diethylamino)ethyl-cellulose column (0.7 × 6 cm, 2.3 mL), 
equilibrated with 50 mM sodium acetate, pH 6.0. The column was then washed with 50 mL of 
the same buffer and eluted with a two-step salt gradient (IE 0.55 and IIE 1.0 M NaCl). Fractions 
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of 1 mL were collected. These were assayed for hexuronate content by the method of Bitter and 
Muir, using glucuronolactone as a standard97. Fractions containing GAGs were pooled and 
precipitated using 4 volumes of cold absolute ethanol. The mixture was left overnight at -20°C 
and the precipitate was separated by centrifugation, washed twice with ethanol, and then dried.  
3.3 Acetate cellulose electrophoresis  
GAG composition was determined by discontinuous electrophoresis according to Cappelletti et 
al.98. This method, combined with the differential susceptibility of GAGs to precipitation by 
solvents, allows optimal and rapid separation of intact GAGs with high resolution and sensitivity 
(10 ng detection limit). GAGs were separated in 0,25 M barium acetate buffer, pH 5.0 by three 
steps. Titan III-H zone cellulose acetate plate (6.0 x 7.5 cm, Helena BioSciences) was first 
dipped in distilled H2O to a height of about 1.5 cm; the sheet was immediately blotted between 
filter papers. The opposite end was then immersed in 0.1 M barium acetate, pH 5.0 for 5.5 cm, 
leaving a narrow band (2 – 4 mm large) apparently dry between H2O and buffer. This band will 
disappeared during the run. The sheet was blotted again between the filter papers, and 5 μl 
sample were applied in the narrow dry band. The loaded sheet was subjected to 5 mA costant 
current for about 6 minutes and then soaked in 0.1 M barium acetate, pH 5.0 for 2 minutes. In the 
next step, a 15 mA costant current was applied for 14 minutes. The sheet was again removed 
from the chamber and immersed for 2 minutes in a similar buffer containing 15% (v/v) ethanol. 
A subsequent electrophoretic step was carried out at 12 mA constant current for 17 minutes. 
After the electrophoresis the sheet was stained in 0.1% (w/v) Alcian Blue solution for 10 
minutes, and destained in 1% (v/v) acetic acid. 
GAGs identification was performed treating aliquots of the samples with specific eliminases, as 
previously described99. The specificity and the efficiency of enzyme treatments were checked on 
standard GAGs under the same experimental conditions. Based on their decreasing 
electrophoretic mobility, standard GAGs run in the following order: chondroitin sulfate 
(C4S/C6S), dermatan sulfate, hyaluronan, heparan sulfate and slow dermatan sulfate. The 
relative percentage of each band per lane was determined by densitometry scanning of Alcian 
Blue stained strips and analyzed with a software. Before the scanning the plate was immersed in 
a solution containing 71% (v/v) methanol, 25% (v/v) acetic acid and 4% (v/v) clear acid to a 
better acquisition of the bands. 
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3.4 GAG depolymerization 
The enzymes that are mainly used for the degradation of the CS isomers or 
galactosaminoglycans (GalAGs), belong to the family of chondro/dermato lyases. All of them 
act on the β(1→4) bond between hexosamine and uronic acid and produce disaccharides 
possessing a double bond between C-4 and C-5 of the uronic acid. The unsaturated uronic acid 
strongly absorbs ultraviolet light at 232 nm (E=5500 M−1 cm−1) and this wavelength is used for 
the quantitation of the products. Chondroitinase ABC, from Proteus Vulgaris, degrades 
hyaluronan (HA), and all chondroitin sulfate isomers (CS A, CS C, and DS), producing 
disaccharide units containing α,β-unsaturated uronic acids: ΔDi-0SHA, ΔDi-0SCS, ΔDi-mono4S, 
ΔDi-mono6S. This enzyme is not active regarding heparin, heparan sulfate and keratan sulfate. 
Chondroitinase AC II, from Arthrobacter Aurescens, acts on the same bond, but it is not able to 
degrade DS, whereas chondroitinase B degrades only DS. A combination of enzymes may also 
be used for the characterization of these GAGs in a biologic sample. Treatment of GalAGs with 
chondroitinase AC II, which completely degrades the CS chains and, to some extent, the DS 
ones, revealed that almost 36% of DS was not degraded by chondroitinase AC II100. 
Dried GAGs were resuspended in 100 μL of 0.1 M ammonium acetate, pH 8.0101. Digestion with 
chondroitinase ABC and chondroitinase AC II was performed at 37 °C for 24 h, using 0.1 U/100 
μg uronic acid. The digestion mixture was boiled for 1 min to inactivate the enzyme, centrifuged 
at 11,000 × g for 5 min, and dried. Then, aliquots were taken for derivatization and FACE 
analysis. 
3.5 Fluorotagging with 2-Aminoacridone (AMAC)  
The free reducing groups that are exposed by enzyme cleavage, can be derivatized with 2-
aminoacridone by reductive amination in the presence of sodium cyanoborohydride (NaBH3CN) 
as described by Calabro et al102 (Fig. 3.1). Particularly, a 40 μL volume of 12.5 mM AMAC 
solution in glacial acetic acid/DMSO (3:17 v/v) was added to the lyophilized sample aliquots, 
and samples were incubated for 10–15 minutes at room temperature. Then 40 μL of 1.25 M 
NaBH3CN in ultrapure water were added to each sample and then mixtures were incubated at 
45°C for 4 hours. After derivatization, 20 μL of glycerol (20% final concentration) were added 
to each sample prior to electrophoresis. If necessary, samples were diluted with buffer containing 
6% glacial acetic acid, 20% glycerol, 34% DMSO, and 480 mM NaBH3CN103. 
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3.6 FACE analysis 
PAGE was performed according to Karousou et al.104, in a MiniProtean II cell vertical slab gel 
electrophoresis apparatus (Bio-Rad). Briefly, the resolving gel consisted of 25%T/3.75%C 
polyacrylamide in a 187.5 mM Tris-borate and 187.5 mM Tris-HCl buffer, pH 8.8. The stacking 
gel was 5%T/1.5%C in 0.36 M Tris-HCl buffer, pH 8.8. A 5 μL volume of each sample was 
loaded in each well; a marker sample containing bromophenol blue was also run in a well with 
no sample. Electrophoresis was performed in 0.15 M Tris-borate, pH 8.8, at 400 V and 4 °C and 
terminated when the marker dye was 1.2 mm from the bottom of the gel. Gels were scanned in a 
UV-light box using a CCD camera (Gel Doc XR System) and analyzed with Quantity One 4.6.3 
from BioRad Laboratories. 
 
Fig. 3.1 - Reducing sugars in solution are in equilibrium (A) between a six-member closed pyranose ring 
conformation and an open conformation containing a free reducing aldehyde (shaded box). The amine group 
(dashed circle) of 2-aminoacridone (AMAC) reacts with the free reducing aldehyde to form a Schiff base (B) that is 
stabilized by reduction with cyanoborohydride (C). The final AMAC-tagged saccharide yields a fluorescent signal 
dependent solely on the fluorotag, not the chemistry of the saccharide. The Rs indicate locations, which may be 
occupied with either a sulfate group or a proton. 
 
3.7 CS calibration curve and statistical analysis 
For quantification of Δ-disaccharide from CS isomers, a CS calibration curve was build using 
commercial chondroitin sulfate A  submitted to chondroitin ABC and AC lyase treatment and 
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derivatization procedure. Data are reported as mean ± standard deviation or total numbers and 
relative frequencies. For comparison between two groups, Student’s t-test was performed. A 
value of P ≤ 0.05 was considered statistically significant. The analyses were performed with 
Microsoft SPSS 11.0 and SigmaStat 3.11.0 software. 
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4. Results and Discussion 
Two main groups of porcine heart valves were analyzed for GAGs determination: aortic valves 
(n = 12) and pulmonary valves (n = 12). For each group, analysis was carried out on six native 
control (NT) and six decellularized samples (TRICOL). From each valve conduit three zones 
were processed: the arterial wall, the commissure or sinus and the leaflet (Fig. 2). 
In Table I total GAG contents, expressed as μg hexuronate/mg DDT, are reported. In both 
valves the three selected areas were significantly different in GAG content83  GAG concentration 
increases moving from the artery wall towards the leaflet. In decellularized aortic valve GAG 
content was significantly reduced in both commissure and leaflet, whereas in pulmonary valves 
the treatment significantly affected only the leaflet. Moreover, the determination of total GAG 
content in native valves indicated higher levels in aortic commissures and leaflets compared to 
the same areas from pulmonary valves. 
Tissue extracted GAGs were freed from proteins and purified by ionic exchange chromatography 
in two steps with different ionic strength (IE and IIE). Typical electrophoresis patterns obtained 
from low and high charge fractions in control and TRICOL samples are shown in Fig. 3. Low 
charge fractions consist of four bands corresponding in order of migration to CSslow, DS HA, HS; 
the high charge fractions show only two bands corresponding to CS and DS. For each band the 
identification was assessed by observing its disappearance following specific enzymatic 
cleavage. GAGs distribution in the three examined areas in both valve conduits is reported in 
Fig. 4. 
In both control valve conduits the leaflets exhibited the highest GAG concentration (see Table 
I), that decreased in commissures and even more in artery walls. GAG analysis indicated that 
deep structural dissimilarities in polysaccharide chains exist depending on their topographic 
localization. In particular, the higher GAG total concentration in sinuses and leaflets is 
associated to higher relative contents of HA and CSslow. 
So, respect to the artery wall, in valves we found a reduced content of heteropolymeric GAGs, 
presenting higher epimerization and sulfation degree and therefore with a greater capability to 
interact with other ECM components, in favour of homopolymeric GAGs, that probably have a 
structural role. Moreover, a slow moving CS isomers seems to be valve tissue-specific. 
GAG levels in aortic root were significantly depleted after decellularization by TRICOL 
treatment. Interestingly, in pulmonary root only the leaflet was significantly affected by the 
treatment. GAG distribution in each native control area was similar for aortic and pulmonary 
roots. Decellularization of native aortic valve induced a massive loss of GAGs from each area 
without changing their relative proportions, indicating that the loss was not selective. On the 
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contrary, decellularization of the pulmonary valve, that greatly affected GAG content of leaflet, 
also produced a deep change in the GAG distribution, suggesting a selective extraction of HA 
and in minor amount of CS, as confirmed by the reduction in CS/DS ratio.  
The concept of decellularization or tissue engineering of heart valves was developed and 
modified by several groups in the course of years. It is believed that the process of 
decellularization can reduce or eliminate the immune response or calcific degeneration 
associated with non autologous cells and cell membranes, thereby increasing implant 
durability105. Nevertheless, decellularization results in a depletion of the spongiosa layer. It has 
been suggested that the principle function of the spongiosa is to dampen the vibrations in the 
fibrosa associated with leaflet flexion during closure. Due to the loss of major GAG component 
in the spongiosa, associated to changes in mechanical and structural properties of decellularized 
leaflets, disruption of the ECM, early tissue degradation, and calcification may result, affecting 
on the durability of the leaflets106. 
The bulk of GAGs in native valve is represented by HA and CS isomers, comprising a slow 
migrating CS. Since the relative proportion of HS in commisures and leaflets of both native 
valves is very little (less than 7%), we focalized on the fine structural characterization of CS 
isomers. The abundance of particular GAGs and PGs can vary according to different biological 
needs of the tissues. For example, the dermatan sulfate (mostly 4-sulfated) PGs decorin and 
biglycan regulate the formation and orientation of collagen fibrils and hence tissue tensile 
strength, whereas the hyaluronan (HA), which is not covalently bound to a core protein, entraps 
large amounts of water to create a swelling force107. It has been speculated that their ability to 
hydrate the spongiosa layer serves to decrease the shear stresses associated with cuspal flexure 
during valve function. In addition, the ability of this hydrated layer to absorb compressive forces 
may reduce buckling during flexion. Furthermore, it has been previously speculated that the 
presence of negatively charged GAG molecules within the extracellular matrix of cuspal tissue 
may reduce calcification by chelating calcium ions, thereby preventing hydroxyapatite 
nucleation66,67,108. Taken together, these observations suggest that the loss of GAGs may be 
crucial for the development of new bioprostheses and tissue engineering. 
GAGs obtained from the three examined areas have been structurally characterized, after ABC 
and AC chondroitinase treatment, by polyacrilamide gel electrophoresis of their constituent Δ-
disaccharides marked with the fluorophore 2-aminoacridone (AMAC). Recent developments in 
carbohydrate analysis using FACE102, have enabled the study of GAGs in heart valves using 
novel and efficient methods. This new technology can quickly provide characteristics about the 
GAG profile, chain lengths, and sulfation patterns that can provide clues to the identity of 
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particular PGs within valve tissues and might be used to postulate their mechanical contributions 
to valve function. In fact FACE is a high sensitivity and resolution method; AMAC is a 
fluorescent molecule with λexc = 425 and λem 520 nm that may be monitored both by UV and LIF 
detection. The derivatization procedure is relatively simple and fast, the derivatization efficiency 
is elevated, and the stability of adduct is satisfactory. Moreover, the excess of derivatizing 
reagent does not interfere with the separation. In Fig. 5 tipical patterns of derivatized Δ-
disaccharides are shown. FACE analyses allow us to detect both mono- and di-sulfate CS 
disaccharides, also discriminating between the non-sulfated forms released from CS isomers and 
those released from HA. In this study, the designation of a GAG as containing iduronate or 
glucuronate was based on the susceptibility to chondroitinase AC II treatment. 
The distributions of Δ-disaccharides from low (A,C) and high (B,D) charge GAGs in each 
selected area (Fig. 6) are similar for control and decellularized valves. Moreover, they did not 
differ in aortic and pulmonary conduits. In Fig. 7 the TRICOL-induced depletions for both total 
and single Δ-disaccharides content (expressed as μg of hexuronate per mg of DDT) are shown. 
The percentages reported near TRICOL bars point out the relative loss for each Δ-disaccharide 
following decellularization procedure, confirming a marked but not selective GAG extraction for 
aortic valve and a lesser extraction, affecting mainly HA, for pulmonary valve. 
Fig. 8 shows the epimerization pattern in both valves for CS isomers in the three examined areas. 
These analyses rely on the knowledge that chondroitinase AC II does not cleave IdoA clusters. 
Native and TRICOL valves, either aortic or pulmonary, did not exhibit significant differences in 
iduronation degree, confirming that CS isomers extraction is not selective (see fig. 7). 
In Table 2 total epimerization patterns for native and TRICOL-treated aortic and pulmonary 
valves are compared. There was no significant difference between control and decellularized 
valves, although it is remarkable that pulmonary valve present a higher iduronation degree than 
aortic conduit. 
Table 3 exhibites Δdi-mono6S/Δdi-mono4S ratio in both valves. In aortic leaflet this ratio was 
significantly reduced after treatment, mostly reflecting CS isomers sulfation from the low charge 
fraction. No significant difference in Δdi-mono6S/Δdi-mono4S ratio was detected after treatment 
of pulmonary conduit. However, by comparing the two types of native valves, significant 
differences were exhibited for low charge GAG fraction from leaflet and arterial wall. In Table 4 
data for CS isomers sulfation degree are reported. TRICOL-treatment does not produce 
significant modifications in total GAG sulfation degree, although it displays some effects on low 
charge GAG fraction from aortic sinus and leaflet. Interestingly, significant differences in the 
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sulfation degree were detected between native aortic and pulmonary valve conduit, regarding 
high charge GAGs. 
In conclusion, results on GAG structural characterization in native and decellularized valves 
suggest that the depletion in total content may also produce changes in GAG distribution. Since 
the structural properties of galactosaminoglycan, such as the extent and pattern of sulfation, the 
charge density, and the isoform of the uronic acid moiety on the GlcA are implicated in their 
bioactivity, their selective modifications could affect the chances of a scaffold for tissue 
engineering. In vivo each of them can be modulated, mediating several biological processes that 
promote the interaction with different molecules. Sulfation pattern is critical for the 
determination of the biological actions of GAGs. Sulfation is also critical for the ionic interaction 
between GalAGs and other molecules. The 5-position carboxylic acid group of GluA is 
synthesized in the glucuronic acid isoform of a chondroitin sulfate galactosaminoglycan but is 
subject to isomerisation, generating the iduronic acid derivative and thus the dermatan sulfate 
galactosaminoglycan. These isomers display different levels of structural flexibility and 
potentially different ionic charge distributions. Compared to the glucuronic acid isoform, the 
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5. Conclusions 
The goal of heart valve tissue engineering is to regenerate a functional structure containing 
endothelial and interstitial cells capable of continuously remodeling the ECM that functions 
structurally and biomechanically as a valve leaflet. Furthermore, it could be used to repair 
congenital defects in children, because bioprostheses have no ability to grow, and therefore 
require more than two replacements, increasing operative risks. Despite an exciting potential for 
tissue engineered heart valves, many unanswered questions remain and significant technical 
barriers must be overcome before widespread clinical application can be envisioned. 
This study shows that, there is a profound loss of GAGs during decellularization procedure. The 
reason for these losses is likely the molecular structure of the proteoglycans that contain these 
GAGs. Distribution of PGs and GAGs in vascular tissue is complex, district- and layer-specific, 
associated with different mechanical environments, and could have important implications for 
heart valve tissue engineering. Although some of these compositional differences may appear 
quite subtle, such as the presence and location of sulfation on GAG chains, these fine structural 
distinctions may have important biological roles such as serving as binding sites for other matrix 
components or for signaling cell differentiation. It is thought that decellularization treatment 
extracts easily hyaluronan and chondroitin/dermatan-6-sulfate, which are those that exist in 
tissues as part of the aggregate of hyaluronan and the proteoglycan versican. Unlike versican, 
core protein of decorin, largely chondroitin/dermatan-4-sulfate, is located adjacent to collagen 
fibrils and could be less susceptible to selective extraction73. 
Although the biosynthetic pathways of CS isomers are known, the mechanisms that regulate 
their post-translational modifications are far to be clear. These post-synthetic events determine 
the huge heterogeneity of GAGs. It is evident that in valvular tissue, GAG metabolism is inusual; 
low sulfation of some CS could be due to lack of sulfation group donors (PAPS) and therefore 
limiting regard to quick turnover. GAG synthesis in this tissues deserves further studies, 
particularly the functional role of low sulfated GAGs, sulfation patterns in general, and 
epimerization degree. The possibility to assess carefully the Δdi-mono4S and Δdi-mono6S 
content in tissues is important because the ratio of these disaccharides changes during aging and 
could be used as a marker of matrix aging111. Moreover, modifications of the Δdi-mono6S/Δdi-
mono4S ratio are thought to play a critical role in diseases112. Furthermore, this ratio might be 
used to hypothesize the type of PGs found in the valves associated to GAG class concentrations 
and fine structure characteristics101. 
Future studies are need to examine the inherent complexity within valve tissues, due to the 
histological layers, mechanical forces, matrix composition and effects of aging, and also the 
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functional characteristic of different GAGs that could have impact on the function of normal 
valves and on the choice of the candidate valve to produce the best scaffold for the development 
of a tissue engineering heart valve. 
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Fig. 1 – Flow diagram showing tissue processing for GAG analysis. 
 
Fig. 2 – Examined tissues. 
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Table 1 - Total GAG content (μg hexuronate/mg DDT) in the selected areas (artery wall, sinus, 
and leaflet) of both valves. t-Test is referred to Control vs Decellularized samples and Pulmonary 
vs Aortic valve. 
p value
Control Decellularized Control vs Decellularized
Artery root wall 5.49 ± 0.59 4.28 ± 1.04 0.033
Commissure 12.99 ± 4.04 10.48 ± 1.96 0.004
Leaflet 16.69 ± 1.64 8.94 ± 1.19 2.93 E-06
p value
Control Decellularized Control vs Decellularized
Artery root wall 5.72 ± 0.91 5.10 ± 0.71 0.22
Commissure 6.98 ± 0.53 5.51 ± 2.38 0.17
Leaflet 10.44 ± 1.73 6.60 ± 2.55 0.012
Pulmonary vs Aortic
Control Decellularized 









Fig. 3 – GAG patterns in low (IE) and high (IIE) charge fractions of NT and TRICOL samples, 
assessed by cellulose acetate electrophoresis. 
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Fig. 4 – GAG distribution in the examined areas of aortic and pulmonary valve conduit. The 
percentages are calculated as sum of GAG distribution in low and high charge fractions. 
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Fig. 5 –FACE separation of unsatured AMAC-labeled disaccharides patterns obtained from low 
(IE) and high charged (IIE) GAGs after depolymerization with Chase ABC and AC. 
Representative patterns for leaflet (panel a), sinus (panel b), and artery wall (panel c) of native 
aortic valve are reported (inverted images). Electrophoresis was performed in 0.15 M Tris 
borate, pH 8.8, at 400 V and 4 °C for 1 h approximately. 
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Fig. 6 – Relative Δ-disaccharides content in low (A and C) and high (B and D) charge GAGs in 
the three native and decellularized examined areas. 
Aortic valve 
Pulmonary valve 
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Fig. 7 – Total Δ-disaccharides content in aortic (A) and pulmonary (B) valves in the three 
examined areas. The percentages in decellularized sample bars are referred to total and single 
loss of Δ-disaccharides following the treatment. 
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Fig. 8 – Representative outline of the epimerization pattern in the selected areas of both valves. 
The percentages are reported as mean values obtained from native and decellularized valves. 
 
 
Table 2 – Total epimerization pattern in the three examined areas of both valves (values are 
means ± standard deviation). 
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Table 3 – CS isomers sulfation pattern in the three examined areas of both valves (values are 
means ± standard deviation). Significant differences are reported in bold  
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Table 4 – Total sulfation degree in the three examined areas of both valves (values are means ± 
standard deviation). Significant differences are reported in bold. 
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